

Contents

WHO Expert Committee on the Selection and Use of Essential Medicines	vii
Declaration of interests	ix
1. Introduction	1
2. Open session	2
Presentation of Subcommittee Report	3
Report on Informal Consultation on Research Priorities for Children's Medicines	5
Other matters	5
Participant statements	6
3. Review of the report of the Subcommittee (including the provisional Model List of Essential Medicines for Children)	7
3.1 General issues	7
3.2 Review of matters referred to the Subcommittee	10
3.3 Review of recommended additions to the list for children	11
3.3.1 Subcutaneous immunoglobulin	11
3.4 Review of responses from applicants to recommendations made by the Subcommittee	11
3.4.1 Artemether injection	11
3.4.2 Artesunate + amodiaquine	13
3.4.3 Artemether + lumefantrine	16
3.4.4 Artesunate + mefloquine	18
3.4.5 Racecadotril	20
3.5 Review of other applications	21
3.6 Review of other comments on the provisional list	21
4. Update on related activities	24
4.1 Report on preliminary work on neonates	24
4.2 Report on research priorities	25
Conclusion	26
References	26
Annex 1	
Report of an Informal Consultation on Research Priorities for Children's Medicines, 2007	27
Annex 2	
First Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines	35
1. Introduction	37

2. Open session	39
3. Policy items	41
3.1 Criteria for the selection of essential medicines for children	41
3.2 Criteria for selection of fixed-dose combination products	44
3.3 Paediatric age categories	45
3.4 Preferred dosage forms	45
3.5 Position paper on off-label use	46
3.6 Review of adherence	47
3.7 Review of regulatory activities	47
4. The WHO Model List of Essential Medicines for Children — by Section	47
Section 1. Anaesthetics	47
Section 2. Analgesics, antipyretics, non-steroidal anti-inflammatory medicines (NSAIDs), medicines used to treat gout and disease modifying agents in rheumatoid disorders (DMARDs)	48
Section 3. Antiallergics and medicines used in anaphylaxis	50
Section 4. Antidotes and other substances used in poisonings	51
Section 5. Anticonvulsants/antiepileptics	52
Section 6. Anti-infective medicines	53
Section 6.1 Anthelmintics	53
Section 6.2 Antibacterials	54
6.2.1 Beta Lactam medicines	54
6.2.2 Other antibacterials	56
6.2.3 Antileprosy medicines	61
6.2.4 Antituberculosis medicines	61
Section 6.3 Antifungal medicines	62
Section 6.4 Antiviral medicines	64
6.4.1 Antiherpes medicines	64
6.4.2 Antiretrovirals	64
New application: Abacavir (scored tablet 300 mg):	
Section 6.4.2.1	66
New application: Lamivudine (scored tablet 150 mg)	66
Fixed-dose combinations	67
New application: Triple fixed-dose combinations	68
6.4.3 Other antivirals	69
Section 6.5 Antiprotozoal medicines	69
6.5.1 Antiamoebic and anti-giardiasis medicines	70
6.5.2 Antileishmaniasis medicines	70
6.5.3 Antimalarial medicines	71
6.5.3.1 For curative treatment	71
6.5.3.2 For prophylaxis	72
New application: Artemether injection	72
New application: Artemether + lumefantrine fixed-dose combination	73
New application: Artesunate (rectal capsules)	75

New application: Artesunate + amodiaquine fixed-dose combination	77
New application: Artesunate + mefloquine fixed-dose combination	79
6.5.4 Medicines for pneumocystis and toxoplasmosis	81
6.5.5 Antitrypanosomal medicines	82
6.5.5.1 African trypanosomiasis	82
6.5.5.2 American trypanosomiasis	82
Section 7. Antimigraine medicines	83
Section 8. Antineoplastic, immunosuppressives and medicines used in palliative care	84
Section 10. Medicines affecting the blood	85
Section 11. Blood products and plasma substitutes	86
Section 11.1 Plasma substitutes	86
Section 11.2 Plasma fractions for specific use (Complementary List)	87
Section 12. Cardiovascular medicines	88
Section 13. Dermatological medicines (topical)	89
Section 13.1 Antifungal medicines	90
Section 13.2 Anti-infective medicines	90
Section 13.3 Anti-inflammatory and antipruritic medicines	90
Section 13.4 Astringent medicines	90
Section 13.5 Medicines affecting skin differentiation and proliferation	91
Section 13.6 Scabicides and pediculicides	91
Section 14. Diagnostic agents	91
Section 15. Disinfectants and antiseptics	92
Section 16. Diuretics	92
Section 17. Gastrointestinal medicines	93
Section 17.1 Antacids and other antiulcer medicines	93
Section 17.2 Antiemetic medicines	93
Section 17.3 Anti-inflammatory medicines	94
Section 17.4 Laxatives	94
Section 17.5 Medicines used in diarrhoea New application: Racecadotril	95
Section 18. Hormones, other endocrine medicines and contraceptives	96
Section 19. Immunologicals	98
Section 20. Muscle relaxants (peripherally-acting) and cholinesterase inhibitors	98
Section 21. Ophthalmological preparations	99
Section 23. Peritoneal dialysis solution	100
Section 24. Psychotherapeutic medicines	100
Section 24.1 Medicines used in psychotic disorders	101
Section 24.2 Medicines used in mood disorders	101
24.2.1 Medicines used in depressive disorders	101
24.2.2 Medicines used in bipolar disorders	102

Section 24.3	<i>Medicines used in generalized anxiety and sleep disorders</i>	102
Section 24.4	<i>Medicines used for obsessive compulsive disorders and panic attacks</i>	102
Section 25.	Medicines acting on the respiratory tract	102
Section 26.	Solutions correcting water, electrolyte and acid-base disturbances	103
Section 27.	Vitamins and minerals	104
5.	Summary of recommendations	105
	Needs identified	105
	Gaps identified	106
	Priorities for reviews	107
	References	107
	Appendix 1	
	Declaration of interests of Subcommittee Members	110
	Appendix 2	
	WHO Model List of Essential Medicines for Children	112
	Appendix 3	
	The Anatomical Therapeutic Chemical (ATC) classification system	142
	Appendix 4	
	Alphabetical list of essential medicines for children (with ATC classification code numbers)	158
	Appendix 5	
	Summary of reviews requested during the Subcommittee meeting	167
	Appendix 6	
	List of individuals and institutions sending in comments to the Subcommittee	173